FIBRONEER-IPF · What does the FVC difference mean?
What the source shows
In 1,177 participants, the 52-week FVC difference versus placebo was 68.8 mL with 18 mg twice daily (95% CI 30.3–107.4).
Boundary of the conclusion
Mean FVC declined in both groups. The difference is neither an individual expected gain nor proof of survival benefit.
Journal Club discussion question
How do background therapy, tolerability and missing measurements affect clinical interpretation? Examine prespecified analyses and the statistical supplement.
The SmPC specifies 18 mg twice daily. Pirfenidone lowers exposure by about 50%, and the dose must not be reduced to 9 mg. A strong CYP3A inhibitor requires 9 mg twice daily.
Boundary of the conclusion
An educational summary of two interactions, not a complete prescribing algorithm. Multiple interactions and adverse effects require a full clinical review.
Journal Club discussion question
What evidence is missing for concomitant pirfenidone and a strong CYP3A inhibitor? Do not assume opposing exposure effects cancel each other.
EMA records EU marketing authorisation of nerandomilast on 15 July 2026 for adults with IPF and PPF.
Why it matters · what remains uncertain
Relevance to care and research
An approved option with a different mechanism. Dosing and co-administration require current product information.
Evidence limitations
EU approval does not establish Greek availability or reimbursement. It is not a cure.
Verified:
Questions about this update
What changed and why does it matter?
EMA records EU marketing authorisation of nerandomilast on 15 July 2026 for adults with IPF and PPF. An approved option with a different mechanism. Dosing and co-administration require current product information.
Which conclusion remains uncertain?
EU approval does not establish Greek availability or reimbursement. It is not a cure.
Critical appraisal question
Which indication and region does the decision cover? Is local access also documented?
Find the answer in the primary source; details absent here have not been confirmed in this summary.
TETON-1: less FVC decline with inhaled treprostinil
The phase 3 trial reports less FVC decline and fewer clinical-worsening events over 52 weeks.
Why it matters · what remains uncertain
Relevance to care and research
Strengthens evidence for an inhaled treatment mechanism in IPF.
Evidence limitations
Cough and discontinuations were common. Publication does not constitute IPF approval or proof of cure or survival benefit.
Verified:
Questions about this update
What changed and why does it matter?
The phase 3 trial reports less FVC decline and fewer clinical-worsening events over 52 weeks. Strengthens evidence for an inhaled treatment mechanism in IPF.
Which conclusion remains uncertain?
Cough and discontinuations were common. Publication does not constitute IPF approval or proof of cure or survival benefit.
Critical appraisal question
Which population was studied, which endpoint was tested, and which alternative interpretations remain?
Find the answer in the primary source; details absent here have not been confirmed in this summary.
In full follow-up, the composite endpoint of exacerbation, respiratory hospitalisation or death did not improve.
Why it matters · what remains uncertain
Relevance to care and research
FVC preservation and survival outcomes need separate interpretation.
Evidence limitations
Numerically lower mortality at 18 mg had a confidence interval crossing 1. An IPF survival benefit was not statistically established.
Verified:
Questions about this update
What changed and why does it matter?
In full follow-up, the composite endpoint of exacerbation, respiratory hospitalisation or death did not improve. FVC preservation and survival outcomes need separate interpretation.
Which conclusion remains uncertain?
Numerically lower mortality at 18 mg had a confidence interval crossing 1. An IPF survival benefit was not statistically established.
Critical appraisal question
Which population was studied, which endpoint was tested, and which alternative interpretations remain?
Find the answer in the primary source; details absent here have not been confirmed in this summary.
The statement extends the framework beyond idiopathic forms and revises selected terms and categories.
Why it matters · what remains uncertain
Relevance to care and research
Supports clearer multidisciplinary assessment and classification of interstitial lung disease.
Evidence limitations
A classification framework, not a new therapy or an automatic change to an individual diagnosis.
Verified:
Questions about this update
What changed and why does it matter?
The statement extends the framework beyond idiopathic forms and revises selected terms and categories. Supports clearer multidisciplinary assessment and classification of interstitial lung disease.
Which conclusion remains uncertain?
A classification framework, not a new therapy or an automatic change to an individual diagnosis.
Critical appraisal question
Which recommendation or classification changed, and to which population does it apply?
Find the answer in the primary source; details absent here have not been confirmed in this summary.
Selected coverage, not an exhaustive news service. Announcements, preprints and investigational treatments are labelled separately. Information does not replace individual medical assessment.
Readings and answers are educational syntheses of the cited sources. They do not represent a personal opinion or stated endorsement by Prof. Demosthenes Bouros. Students can access this page freely without an account.